Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues

Wei Chen, Jiancheng Zhou, Kaijie Wu, Jun Huang, Ye Ding, Eun Jin Yun, Bin Wang, Chunyong Ding, Elizabeth Hernandez, John Santoyo, Haiying Chen, Ho Lin, Arthur Sagalowsky, Dalin He, Jia Zhou, Jer Tsong Hsieh

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Conventional chemotherapy is commonly used for advanced stages of transitional cell carcinoma (TCC) with modest success and high morbidity; however, TCC eventually develops resistance. Muscle invasive bladder cancer (MIBC) is recognized as a lethal disease due to its poor response to traditional chemotherapy. Numerous studies have implicated β-catenin, a critical effector in Wnt-mediated pathway associated with epithelial-mesenchymal transition and cancer stem cell, is involved in TCC progression, and furthermore closely associated with chemo-resistance. In this study, we discovered a novel natural product analogue CYD 6-17 that has a potent inhibitory effect on TCC cells exhibiting drug resistance to various chemotherapeutics, with an IC50 at nM range. Delivery of CYD 6-17 significantly inhibited the tumor growth using xenograft model but without detectable side effects. Mechanistically, it targeted β-catenin gene transcription by decreasing the binding of XBP1 to the promoter region, which appeared to be a new regulatory mechanism for β-catenin gene expression. Clinically, XBP1 expression correlated with the poor overall survival of patients. Overall, this study unveils unique mechanism of β-catenin gene regulation in advanced TCC and also offers a potential rational therapeutic regimen to MIBC.

Original languageEnglish (US)
Pages (from-to)56842-56854
Number of pages13
JournalOncotarget
Volume7
Issue number35
DOIs
StatePublished - 2016

Fingerprint

Catenins
Transitional Cell Carcinoma
Urinary Bladder Neoplasms
Drug Therapy
Muscles
Wnt Signaling Pathway
Epithelial-Mesenchymal Transition
Neoplastic Stem Cells
Biological Products
Mesenchymal Stromal Cells
Drug Resistance
Heterografts
Genetic Promoter Regions
Genes
Inhibitory Concentration 50
oridonin
Morbidity
Gene Expression
Survival
Growth

Keywords

  • Oridonin
  • Transitional cell carcinoma
  • Wnt pathway
  • XBP1
  • β-catenin

ASJC Scopus subject areas

  • Oncology

Cite this

Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues. / Chen, Wei; Zhou, Jiancheng; Wu, Kaijie; Huang, Jun; Ding, Ye; Yun, Eun Jin; Wang, Bin; Ding, Chunyong; Hernandez, Elizabeth; Santoyo, John; Chen, Haiying; Lin, Ho; Sagalowsky, Arthur; He, Dalin; Zhou, Jia; Hsieh, Jer Tsong.

In: Oncotarget, Vol. 7, No. 35, 2016, p. 56842-56854.

Research output: Contribution to journalArticle

Chen, W, Zhou, J, Wu, K, Huang, J, Ding, Y, Yun, EJ, Wang, B, Ding, C, Hernandez, E, Santoyo, J, Chen, H, Lin, H, Sagalowsky, A, He, D, Zhou, J & Hsieh, JT 2016, 'Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues', Oncotarget, vol. 7, no. 35, pp. 56842-56854. https://doi.org/10.18632/oncotarget.10863
Chen, Wei ; Zhou, Jiancheng ; Wu, Kaijie ; Huang, Jun ; Ding, Ye ; Yun, Eun Jin ; Wang, Bin ; Ding, Chunyong ; Hernandez, Elizabeth ; Santoyo, John ; Chen, Haiying ; Lin, Ho ; Sagalowsky, Arthur ; He, Dalin ; Zhou, Jia ; Hsieh, Jer Tsong. / Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues. In: Oncotarget. 2016 ; Vol. 7, No. 35. pp. 56842-56854.
@article{8843da7f93ea4d9f8a78cc6909ff634b,
title = "Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues",
abstract = "Conventional chemotherapy is commonly used for advanced stages of transitional cell carcinoma (TCC) with modest success and high morbidity; however, TCC eventually develops resistance. Muscle invasive bladder cancer (MIBC) is recognized as a lethal disease due to its poor response to traditional chemotherapy. Numerous studies have implicated β-catenin, a critical effector in Wnt-mediated pathway associated with epithelial-mesenchymal transition and cancer stem cell, is involved in TCC progression, and furthermore closely associated with chemo-resistance. In this study, we discovered a novel natural product analogue CYD 6-17 that has a potent inhibitory effect on TCC cells exhibiting drug resistance to various chemotherapeutics, with an IC50 at nM range. Delivery of CYD 6-17 significantly inhibited the tumor growth using xenograft model but without detectable side effects. Mechanistically, it targeted β-catenin gene transcription by decreasing the binding of XBP1 to the promoter region, which appeared to be a new regulatory mechanism for β-catenin gene expression. Clinically, XBP1 expression correlated with the poor overall survival of patients. Overall, this study unveils unique mechanism of β-catenin gene regulation in advanced TCC and also offers a potential rational therapeutic regimen to MIBC.",
keywords = "Oridonin, Transitional cell carcinoma, Wnt pathway, XBP1, β-catenin",
author = "Wei Chen and Jiancheng Zhou and Kaijie Wu and Jun Huang and Ye Ding and Yun, {Eun Jin} and Bin Wang and Chunyong Ding and Elizabeth Hernandez and John Santoyo and Haiying Chen and Ho Lin and Arthur Sagalowsky and Dalin He and Jia Zhou and Hsieh, {Jer Tsong}",
year = "2016",
doi = "10.18632/oncotarget.10863",
language = "English (US)",
volume = "7",
pages = "56842--56854",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "35",

}

TY - JOUR

T1 - Targeting XBP1-mediated β-catenin expression associated with bladder cancer with newly synthetic Oridonin analogues

AU - Chen, Wei

AU - Zhou, Jiancheng

AU - Wu, Kaijie

AU - Huang, Jun

AU - Ding, Ye

AU - Yun, Eun Jin

AU - Wang, Bin

AU - Ding, Chunyong

AU - Hernandez, Elizabeth

AU - Santoyo, John

AU - Chen, Haiying

AU - Lin, Ho

AU - Sagalowsky, Arthur

AU - He, Dalin

AU - Zhou, Jia

AU - Hsieh, Jer Tsong

PY - 2016

Y1 - 2016

N2 - Conventional chemotherapy is commonly used for advanced stages of transitional cell carcinoma (TCC) with modest success and high morbidity; however, TCC eventually develops resistance. Muscle invasive bladder cancer (MIBC) is recognized as a lethal disease due to its poor response to traditional chemotherapy. Numerous studies have implicated β-catenin, a critical effector in Wnt-mediated pathway associated with epithelial-mesenchymal transition and cancer stem cell, is involved in TCC progression, and furthermore closely associated with chemo-resistance. In this study, we discovered a novel natural product analogue CYD 6-17 that has a potent inhibitory effect on TCC cells exhibiting drug resistance to various chemotherapeutics, with an IC50 at nM range. Delivery of CYD 6-17 significantly inhibited the tumor growth using xenograft model but without detectable side effects. Mechanistically, it targeted β-catenin gene transcription by decreasing the binding of XBP1 to the promoter region, which appeared to be a new regulatory mechanism for β-catenin gene expression. Clinically, XBP1 expression correlated with the poor overall survival of patients. Overall, this study unveils unique mechanism of β-catenin gene regulation in advanced TCC and also offers a potential rational therapeutic regimen to MIBC.

AB - Conventional chemotherapy is commonly used for advanced stages of transitional cell carcinoma (TCC) with modest success and high morbidity; however, TCC eventually develops resistance. Muscle invasive bladder cancer (MIBC) is recognized as a lethal disease due to its poor response to traditional chemotherapy. Numerous studies have implicated β-catenin, a critical effector in Wnt-mediated pathway associated with epithelial-mesenchymal transition and cancer stem cell, is involved in TCC progression, and furthermore closely associated with chemo-resistance. In this study, we discovered a novel natural product analogue CYD 6-17 that has a potent inhibitory effect on TCC cells exhibiting drug resistance to various chemotherapeutics, with an IC50 at nM range. Delivery of CYD 6-17 significantly inhibited the tumor growth using xenograft model but without detectable side effects. Mechanistically, it targeted β-catenin gene transcription by decreasing the binding of XBP1 to the promoter region, which appeared to be a new regulatory mechanism for β-catenin gene expression. Clinically, XBP1 expression correlated with the poor overall survival of patients. Overall, this study unveils unique mechanism of β-catenin gene regulation in advanced TCC and also offers a potential rational therapeutic regimen to MIBC.

KW - Oridonin

KW - Transitional cell carcinoma

KW - Wnt pathway

KW - XBP1

KW - β-catenin

UR - http://www.scopus.com/inward/record.url?scp=84984878615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984878615&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.10863

DO - 10.18632/oncotarget.10863

M3 - Article

VL - 7

SP - 56842

EP - 56854

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 35

ER -